3-isopropylphenyl isothiocyanate | 611226-39-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-isopropylphenyl isothiocyanate
• 英文别名: 3-isopropylbenzeneisothiocyanate；1-Isothiocyanato-3-(propan-2-yl)benzene；1-isothiocyanato-3-propan-2-ylbenzene
• CAS: 611226-39-2
• 化学式: C₁₀H₁₁NS
• mdl: MFCD11193565
• 分子量: 177.27
• InChiKey: DEJVUVMZSJGRSF-UHFFFAOYSA-N

物化性质

• 沸点：
  267.0±19.0 °C(Predicted)
• 密度：
  1.00±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  44.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-isopropylphenyl isothiocyanate 在 sodium hydride 、 potassium carbonate 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.5h， 生成
  参考文献：
  名称：

  2-Arylimino-5,6-dihydro-4H-1,3-thiazines as a new class of cannabinoid receptor agonists. Part 2: Orally bioavailable compounds

  摘要：

  Structure-activity; relationships and efforts to optimize the pharmacokinetic profile of a class of 2-arylimino-5,6-dihydro4H-1,3-thiazines as cannabinoid receptor agonists are described. Among the compounds examined, compound 14 showed potent affinity and high selectivity for CB2, and compound 23 showed potent affinities against CB1 and CB2. These compounds displayed oral bioavailability. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.04.099
• 作为产物：
  描述：

  硫光气 、 3-异丙基苯胺 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 生成 3-isopropylphenyl isothiocyanate
  参考文献：
  名称：

  Inhibitors of the Diadenosine Tetraphosphate Phosphorylase Rv2613c of Mycobacterium tuberculosis

  摘要：

  The intracellular concentration of diadenosine tetraphospate (Ap(4)A) increases upon exposure to stress conditions. Despite being discovered over 50 years ago, the cellular functions of Ap(4)A are still enigmatic. If and how the varied Ap(4)A is a signal and involved in the signaling pathways leading to an appropriate cellular response remain to be discovered. Because the turnover of Ap(4)A by Ap(4)A cleaving enzymes is rapid, small molecule inhibitors for these enzymes would provide tools for the more detailed study of the role of Ap(4)A. Here, we describe the development of a high-throughput screening assay based on a fluorogenic Ap(4)A substrate for the identification and optimization of small molecule inhibitors for Ap(4)A cleaving enzymes. As proof-of-concept we screened a library of over 42 000 compounds toward their inhibitory activity against the Ap(4)A phosphorylase (Rv2613c) of Mycobacterium tuberculosis (Mtb). A sulfanylacrylonitril derivative with an IC50 of 260 +/- 50 nM in vitro was identified. Multiple derivatives were synthesized to further optimize their properties with respect to their in vitro IC50 values and their cytotoxicity against human cells (HeLa). In addition, we selected two hits to study their antimycobacterial activity against virulent Mtb to show that they might be candidates for further development of antimycobacterial agents against multidrug-resistant Mtb.

  DOI：

  10.1021/acschembio.7b00653

文献信息

• Substituted benzazoles and methods of their use as inhibitors of Raf kinase
  申请人：——

  公开号：US20040122237A1

  公开（公告）日：2004-06-24

  New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.

  提供了新的替代苯唑化合物、组合物和抑制人类或动物主体中Raf激酶活性的方法。这些新化合物组合物可以单独使用，也可以与至少一种额外药物结合，用于治疗由Raf激酶介导的疾病，如癌症。
• One-Pot Synthesis of Benzimidazo[2,1-<i>b</i>]thiazoline Derivatives through an Addition/Cyclization/Oxidative Coupling Reaction
  作者：Haofeng Wang、Xin Wu、Luyu Wang、Erfei Li、Xiaoyu Li、Tao Tong、Honglan Kang、Jianwu Xie、Guodong Shen、Xin Lv

  DOI：10.1021/acs.joc.0c01137

  日期：2020.9.18

  A novel and efficient approach to the synthesis of benzimidazo[2,1-b]thiazoline derivatives has been developed through an addition/cyclization/intramolecular oxidative C–H functionalization process. A variety of alkylene benzimidazo[2,1-b] thiazolines were conveniently assembled from the reaction of aryl isothiocyanate and propargylic amine in the presence of Cu(OAc)2 and PIFA at room temperature.

  通过加成/环化/分子内氧化C–H官能化过程，已开发出一种新颖且有效的合成苯并咪唑[2,1- b ]噻唑啉衍生物的方法。在室温下，在Cu（OAc）2和PIFA存在下，由异硫氰酸芳基酯和炔丙基胺反应可方便地组装各种亚烷基苯并咪唑并[2,1- b ]噻唑啉。该产物可以进一步转化为取代的苯并咪唑并[2，1- b ]噻唑衍生物。
• [EN] SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF RAF KINASE<br/>[FR] BENZAZOLES SUBSTITUES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE LA RAF KINASE
  申请人：CHIRON CORP

  公开号：WO2005037273A1

  公开（公告）日：2005-04-28

  New substituted benzazole compounds of formula (I), compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.

  提供式(I)的新取代苯并咪唑化合物、组合物和用于抑制人或动物主体中Raf激酶活性的方法。这些新化合物组合物可以单独使用，也可以与至少一种其他药物联合使用，用于治疗Raf激酶介导的疾病，如癌症。
• Substituted benz-azoles and methods of their use as inhibitors of Raf kinase
  申请人：——

  公开号：US20040087626A1

  公开（公告）日：2004-05-06

  New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.

  提供了新的取代苯并咪唑化合物、组合物和抑制人类或动物主体中Raf激酶活性的方法。这些新的化合物组合物可以单独使用或与至少一种其他药物联合使用，用于治疗Raf激酶介导的疾病，如癌症。
• Substituted Benzazoles and Methods of Their Use as Inhibitors of RAF Kinase
  申请人：COSTALES Abran

  公开号：US20090035309A1

  公开（公告）日：2009-02-05

  New substituted benzazole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.

  本发明提供了新的取代苯并咪唑化合物、组合物和抑制人或动物体内Raf激酶活性的方法。这些新化合物组合物可以单独使用或与至少一种其他药物联合使用，用于治疗Raf激酶介导的疾病，如癌症。